

Amendments to the Claims:

The listing of claims set forth below is to replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

Claim 1 (canceled).

Claim 2 (canceled).

Claim 3 (canceled).

Claim 4 (canceled).

Claim 5 (canceled).

Claim 6 (canceled).

Claim 7 (canceled).

Claim 8 (canceled).

Claim 9 (canceled).

Claim 10 (canceled).

Claim 11 (canceled).

Claim 12 (canceled).

Claim 13 (canceled).

Claim 14 (canceled).

Claim 15 (canceled).

Claim 16 (canceled).

Claim 17 (canceled).

Claim 18 (canceled).

Claim 19 (canceled).

Claim 20 (canceled).

Claim 21 (previously presented): A composition comprising:
a first $\alpha_3\beta_4$ nicotinic receptor antagonist; and
a second $\alpha_3\beta_4$ nicotinic receptor antagonist; wherein
the second $\alpha_3\beta_4$ nicotinic receptor antagonist is different than
the first $\alpha_3\beta_4$ nicotinic receptor antagonist;
provided that, when the first $\alpha_3\beta_4$ nicotinic receptor
antagonist is dextromethorphan, the second $\alpha_3\beta_4$ nicotinic
receptor antagonist is not dextrorphan; and
further provided that, when the first $\alpha_3\beta_4$ nicotinic
receptor antagonist is dextrorphan, the second $\alpha_3\beta_4$ nicotinic
receptor antagonist is not dextromethorphan; and
further provided that, when first $\alpha_3\beta_4$ nicotinic
receptor antagonist is dextromethorphan, dextrorphan, or
mecamylamine, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is
not bupropion; and

further provided that, when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is bupropion, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextromethorphan, dextrorphan, or mecamylamine.

Claim 22 (original): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist and said second $\alpha_3\beta_4$ nicotinic receptor antagonist are present in a weight ratio of from about 10:1 to about 1:10.

Claim 23 (original): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist and said second $\alpha_3\beta_4$ nicotinic receptor antagonist are present in a weight ratio of from about 5:1 to about 1:5.

Claim 24 (original): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist is selected from the group consisting of mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof.

Claim 25 (original): A composition according to claim 21, wherein said second $\alpha_3\beta_4$ nicotinic receptor antagonist is selected from the group consisting of mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof.

Claim 26 (original): A composition according to claim 21, wherein each of said first and said second $\alpha_3\beta_4$ nicotinic receptor antagonists is independently selected from the group consisting of mecamylamine, 18-methoxycoronaridine, bupropion,

dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof.

Claim 27 (withdrawn): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist is mecamylamine.

Claim 28 (original): A composition according to claim 21, wherein said second $\alpha_3\beta_4$ nicotinic receptor antagonist is dextromethorphan.

Claim 29 (withdrawn): A composition according to claim 21, wherein said second $\alpha_3\beta_4$ nicotinic receptor antagonist is dextrorphan.

Claim 30 (withdrawn): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist is mecamylamine and wherein said second $\alpha_3\beta_4$ nicotinic receptor antagonist is dextromethorphan.

Claim 31 (withdrawn): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist is mecamylamine and wherein said second $\alpha_3\beta_4$ nicotinic receptor antagonist is dextrorphan.

Claim 32 (original): A composition according to claim 21, wherein said composition is in the form of a tablet, capsule, granular dispersible powder, suspension, syrup, or elixir.

Claim 33 (original): A composition according to claim 21, wherein said composition is in the form of a tablet or capsule

and wherein said composition further comprises an inert diluent, a granulating agent, a disintegrating agent, a lubricating agent, or combinations thereof.

Claim 34 (previously presented): A composition comprising:

a first compound selected from the group consisting of mecamlamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof; and

a second compound selected from the group consisting of mecamlamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof; wherein the second compound is different than the first compound;

provided that, when the first compound is dextromethorphan, the second compound is not dextrorphan; and

further provided that, when the first compound is dextrorphan, the second compound is not dextromethorphan; and

further provided that, when first compound is dextromethorphan, dextrorphan, or mecamlamine, the second compound is not bupropion; and

further provided that, when the first compound is bupropion, the second compound is not dextromethorphan, dextrorphan, or mecamlamine.

Claim 35 (canceled).

Claim 36 (canceled).

Claim 37 (canceled).

Claim 38 (canceled).

Claim 39 (canceled).

Claim 40 (canceled).

Claim 41 (canceled).

Claim 42 (canceled).

Claim 43 (canceled).

Claim 44 (canceled).

Claim 45 (withdrawn): A composition according to claim 21, wherein said first $\alpha_3\beta_4$ nicotinic receptor antagonist is neither dextrorphan nor dextromethorphan and wherein said second $\alpha_3\beta_4$ nicotinic receptor antagonist is neither dextrorphan nor dextromethorphan.

Claim 46 (previously presented): A composition according to claim 21, wherein one of said first and second $\alpha_3\beta_4$ nicotinic receptor antagonists is 18-methoxycoronaridine or a pharmaceutically acceptable salt or solvate thereof.

Claim 47 (canceled).

Claim 48 (canceled).

Claim 49 (canceled).

Claim 50 (canceled).